New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2020, 383 (6), pp.546-557. ⟨10.1056/NEJMoa1917246⟩ The New England journal of medicine New England Journal of Medicine, 2020, 383 (6), pp.546-557. ⟨10.1056/NEJMoa1917246⟩ The New England journal of medicine, Vol. 383, no. 6, p. 546-557 (2020)
Lancet, Vol. 380, no.9856, p. 1829-39 (2012) Lancet, 380(9856), 1829-1839. Elsevier Science Coles, A J, Twyman, C L, Arnold, D L, Cohen, J A, Confavreux, C, Fox, E J, Hartung, H P, Havrdova, E, Selmaj, K W, Weiner, H L, Miller, T, Fisher, E, Sandbrink, R, Lake, S L, Margolin, D H, Oyuela, P, Barkhof, F, Panzara, M A & Compston, D 2012, ' Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial ', Lancet, vol. 380, no. 9856, pp. 1829-1839 . https://doi.org/10.1016/S0140-6736(12)61768-1 Lancet, 380(9856), 1829-1839. Elsevier Limited